Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Commentary|Videos|June 30, 2026
The Oncology Care Model: A Decade of Transformation
Fact checked by: Christina Mattina
Seven oncology leaders reflect on lasting gains in patient care, cost awareness, and collaboration, and what was lost when CMS walked away.
Advertisement
Advertisement
Seven oncology leaders reflected on the
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement